Annexon_Logo_RGB.png
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
June 07, 2022 06:30 ET | Annexon Biosciences
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month StudyRapid Improvement in Clinical...
Annexon_Logo_RGB.png
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 06:30 ET | Annexon Biosciences
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon_Logo_RGB.png
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
June 01, 2022 07:30 ET | Annexon Biosciences
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon_Logo_RGB.png
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET | Annexon Biosciences
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023...
Annexon_Logo_RGB.png
Annexon Biosciences to Participate in Upcoming May Investor Conferences
May 05, 2022 06:30 ET | Annexon Biosciences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
Annexon_Logo_RGB.png
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
April 07, 2022 06:30 ET | Annexon Biosciences
BRISBANE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon_Logo_RGB.png
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 04, 2022 06:30 ET | Annexon Biosciences
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon_Logo_RGB.png
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
March 03, 2022 16:01 ET | Annexon Biosciences
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon_Logo_RGB.png
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:01 ET | Annexon Biosciences
Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Huntington’s Disease; Full Data...
Annexon_Logo_RGB.png
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
February 28, 2022 06:30 ET | Annexon Biosciences
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...